Supportive Care in Cancer

, Volume 22, Issue 8, pp 2281–2295 | Cite as

Management options for established chemotherapy-induced peripheral neuropathy

  • Deirdre R. PachmanEmail author
  • James C. Watson
  • Maryam B. Lustberg
  • Nina D. Wagner-Johnston
  • Alexandre Chan
  • Larry Broadfield
  • Yin Ting Cheung
  • Christopher Steer
  • Dawn J. Storey
  • Kavita D. Chandwani
  • Judith Paice
  • Pascal Jean-Pierre
  • Jeong Oh
  • Jayesh Kamath
  • Marie Fallon
  • Herwig Strik
  • Susanne Koeppen
  • Charles L. Loprinzi
Review Article


Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients’ psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.


Chemotherapy-induced peripheral neuropathy CIPN Neuropathy 


Conflict of interest

The authors do not have a financial relationship with the organization that sponsored the research. All author disclosures are included in the attached author disclosure forms. This is a review article, and the primary author has full control of all primary data and agrees to allow the journal to review data if requested.


  1. 1.
    Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094PubMedCrossRefGoogle Scholar
  2. 2.
    Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767–774PubMedCrossRefGoogle Scholar
  3. 3.
    Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708–716PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059–2066PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Tofthagen C, Overcash J, Kip K (2012) Falls in persons with chemotherapy-induced peripheral neuropathy supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 20: 583–589Google Scholar
  6. 6.
    Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848Google Scholar
  7. 7.
    Dworkin RH, Turk DC, Basch E, Berger A, Cleeland C, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Markman J, Porter L, Raja SN, Ross E, Todd K, Wallace M, Woolf CJ (2011) Considerations for extrapolating evidence of acute and chronic pain analgesic efficacy. Pain 152:1705–1708PubMedCrossRefGoogle Scholar
  8. 8.
    Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, Dougherty PM (2011) Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain Off J Am Pain Soc 12:1017–1024CrossRefGoogle Scholar
  9. 9.
    Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109:132–142PubMedCrossRefGoogle Scholar
  10. 10.
    Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625–632PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Tzeng CH, Wang WS, Chiang HL, Teng CJ, Teng HW (2011) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care CancerGoogle Scholar
  12. 12.
    Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309:1359–1367CrossRefGoogle Scholar
  13. 13.
    Durand JP, Alexandre J, Guillevin L, Goldwasser F (2005) Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 16:587–591PubMedCrossRefGoogle Scholar
  14. 14.
    Durand JP, Goldwasser F (2002) Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anticancer Drugs 13:777–780PubMedCrossRefGoogle Scholar
  15. 15.
    Ozdogan MSM, Bozcuk HS et al (2004) Venlafaxine for treatment of chemotherapy-induced neuropathic pain. Turk J Cancer 34:110–112Google Scholar
  16. 16.
    Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM Jr, Stella PJ, Johnson JA (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203PubMedCrossRefGoogle Scholar
  17. 17.
    Kautio AL, Haanpaa M, Saarto T, Kalso E (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31–39PubMedCrossRefGoogle Scholar
  18. 18.
    Mariani G et al. (2000) Oxaliplatin induced neuropathy: could gabapentin be the answer? Proc Am Soc Clin Oncol 19 (abstract 2397)Google Scholar
  19. 19.
    Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRefGoogle Scholar
  20. 20.
    Saif MW, Syrigos K, Kaley K, Isufi I (2010) Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 30:2927–2933PubMedGoogle Scholar
  21. 21.
    Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802–2808PubMedCrossRefGoogle Scholar
  22. 22.
    Liu YC, Wang WS (2012) Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer 118:1718–1725PubMedCrossRefGoogle Scholar
  23. 23.
    Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D’Elia GM, Truini A, Niscola P, Petrucci MT (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Support Care Cancer 20:2621–2626PubMedCrossRefGoogle Scholar
  24. 24.
    Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr., Riepl M, Christensen B, Loprinzi CL (2010) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care CancerGoogle Scholar
  25. 25.
    Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR (2014) A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care CancerGoogle Scholar
  26. 26.
    Storey LAC, Scott AC, Boyle D, Green L, Jones AP, Fallon MT (2010) Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: a phase I study. J Clin Oncol 28(15s) (supple;abstr 9129)Google Scholar
  27. 27.
    Gedlicka C, Kornek GV, Schmid K, Scheithauer W (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14:339–340PubMedCrossRefGoogle Scholar
  28. 28.
    Gedlicka C, Scheithauer W, Schull B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20:3359–3361PubMedCrossRefGoogle Scholar
  29. 29.
    Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750PubMedCrossRefGoogle Scholar
  30. 30.
    Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L (2005) A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91:135–138PubMedGoogle Scholar
  31. 31.
    Sun Y (2012) A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 30 (suppl; abstr 9017)Google Scholar
  32. 32.
    Ray WA, Meredith S, Thapa PB, Hall K, Murray KT (2004) Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 75:234–241PubMedCrossRefGoogle Scholar
  33. 33.
    Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–251PubMedCrossRefGoogle Scholar
  34. 34.
    Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3–S14PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109–118PubMedCrossRefGoogle Scholar
  36. 36.
    Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, Wernicke JF (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6:346–356PubMedCrossRefGoogle Scholar
  37. 37.
    Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, Raskin J (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411–1420PubMedCrossRefGoogle Scholar
  38. 38.
    Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D (2011) Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation Neurology 76: 1758–1765Google Scholar
  39. 39.
    O’Connor AB, Dworkin RH (2009) Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 122:S22–S32PubMedCrossRefGoogle Scholar
  40. 40.
    Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME (2008) The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 22:241–245PubMedCrossRefGoogle Scholar
  41. 41.
    Rowbotham MC, Goli V, Kunz NR, Lei D (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110:697–706PubMedCrossRefGoogle Scholar
  42. 42.
    Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60:1284–1289PubMedCrossRefGoogle Scholar
  43. 43.
    Durand JP, Brezault C, Goldwasser F (2003) Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 14:423–425PubMedCrossRefGoogle Scholar
  44. 44.
    Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200–205PubMedCrossRefGoogle Scholar
  45. 45.
    Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev CD005454Google Scholar
  46. 46.
    Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836PubMedCrossRefGoogle Scholar
  47. 47.
    Serpell MG (2002) Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 99:557–566PubMedCrossRefGoogle Scholar
  48. 48.
    Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661–669PubMedCrossRefGoogle Scholar
  49. 49.
    Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L (2008) Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 8:33PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Freeman R, Durso-Decruz E, Emir B (2008) Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 31:1448–1454PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253–260PubMedCrossRefGoogle Scholar
  52. 52.
    Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr (2008) Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 12:203–213PubMedCrossRefGoogle Scholar
  53. 53.
    Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, Pagouni E, Pikazis D, Zis PV, Koufos C (2008) Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 9:1209–1216PubMedCrossRefGoogle Scholar
  54. 54.
    Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27:490–497PubMedCrossRefGoogle Scholar
  55. 55.
    Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505–509PubMedCrossRefGoogle Scholar
  56. 56.
    Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60:1508–1514PubMedCrossRefGoogle Scholar
  57. 57.
    Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54:2115–2119PubMedCrossRefGoogle Scholar
  58. 58.
    Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS (2001) Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56:184–190PubMedCrossRefGoogle Scholar
  59. 59.
    Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96:375–383PubMedCrossRefGoogle Scholar
  60. 60.
    McCleane G (1999) 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 83:105PubMedCrossRefGoogle Scholar
  61. 61.
    Silver M, Blum D, Grainger J, Hammer AE, Quessy S (2007) Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 34:446–454PubMedCrossRefGoogle Scholar
  62. 62.
    Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, Quessy S, Blum D, Grainger J, White J, Silver M (2007) Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 128:169–179PubMedCrossRefGoogle Scholar
  63. 63.
    Wiffen PJ, Derry S, Moore RA (2011) Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev CD006044Google Scholar
  64. 64.
    Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB (2002) Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59:1015–1021PubMedCrossRefGoogle Scholar
  65. 65.
    Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348:1223–1232PubMedCrossRefGoogle Scholar
  66. 66.
    Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60:927–934PubMedCrossRefGoogle Scholar
  67. 67.
    Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71–78PubMedCrossRefGoogle Scholar
  68. 68.
    Franek M, Vaculin S, Rokyta R (2004) GABA(B) receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in the rat. Physiol Res 53:351–355PubMedGoogle Scholar
  69. 69.
    Gammaitoni A, Gallagher RM, Welz-Bosna M (2000) Topical ketamine gel: possible role in treating neuropathic pain. Pain Med 1:97–100PubMedCrossRefGoogle Scholar
  70. 70.
    Lynch ME, Clark AJ, Sawynok J (2003) A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain 19:323–328PubMedCrossRefGoogle Scholar
  71. 71.
    Lynch ME, Clark AJ, Sawynok J, Sullivan MJ (2005) Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology 103:140–146PubMedCrossRefGoogle Scholar
  72. 72.
    Lynch ME, Clark AJ, Sawynok J, Sullivan MJ (2005) Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain 6:644–649PubMedCrossRefGoogle Scholar
  73. 73.
    Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, Fleetwood-Walker SM, Mitchell R (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16:1591–1605PubMedCrossRefGoogle Scholar
  74. 74.
    Davies SJ, Harding LM, Baranowski AP (2002) A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 18:200–202PubMedCrossRefGoogle Scholar
  75. 75.
    Wasner G, Naleschinski D, Binder A, Schattschneider J, McLachlan EM, Baron R (2008) The effect of menthol on cold allodynia in patients with neuropathic pain. Pain Med 9:354–358PubMedCrossRefGoogle Scholar
  76. 76.
    Colvin LA, Johnson PR, Mitchell R, Fleetwood-Walker SM, Fallon M (2008) From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 26:4519–4520PubMedCrossRefGoogle Scholar
  77. 77.
    Storey DJ, Colvin LA, Mackean MJ, Mitchell R, Fleetwood-Walker SM, Fallon MT (2010) Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. J Pain Symptom Manage 39:e2–e4PubMedCrossRefGoogle Scholar
  78. 78.
    Storey DJ, Boyle LA, Scott D et al (2011) Topical menthol: a novel intervention that improved chemotherapy induced peripheral neuropathy (CIPN) related pain and physical function. Support Care Cancer 10:S158Google Scholar
  79. 79.
    Bley KR (2004) Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs 13:1445–1456PubMedCrossRefGoogle Scholar
  80. 80.
    Derry S, Moore RA (2012) Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9: CD010111Google Scholar
  81. 81.
    Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, Tobias J, Group N-CS (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7:1106–1112PubMedCrossRefGoogle Scholar
  82. 82.
    Simpson DM, Brown S, Tobias J, Group N-CS (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70:2305–2313PubMedCrossRefGoogle Scholar
  83. 83.
    Derry S, Sven-Rice A, Cole P, Tan T, Moore RA (2013) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2: CD007393Google Scholar
  84. 84.
    Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160–1167PubMedCrossRefGoogle Scholar
  85. 85.
    Ziegler D, Nowak H, Kempler P, Vargha P, Low PA (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21:114–121PubMedCrossRefGoogle Scholar
  86. 86.
    Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29:2365–2370PubMedCrossRefGoogle Scholar
  87. 87.
    Guo YPL, Forman A, Dakhil S R, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fish M (2011) A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. J Clin Oncol 29Google Scholar
  88. 88.
    Scafidi S, Fiskum G, Lindauer SL, Bamford P, Shi D, Hopkins I, McKenna MC (2010) Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the immature rat brain. J Neurochem 114:820–831PubMedCrossRefGoogle Scholar
  89. 89.
    Chiechio S, Copani A, Gereau RW, Nicoletti F (2007) Acetyl-L-carnitine in neuropathic pain: experimental data CNS. Drugs 21(Suppl 1):31–38, discussion 45–36Google Scholar
  90. 90.
    De Grandis D (2007) Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review CNS. Drugs 21(Suppl 1):39–43, discussion 45–36Google Scholar
  91. 91.
    Evans JD, Jacobs TF, Evans EW (2008) Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 42:1686–1691PubMedCrossRefGoogle Scholar
  92. 92.
    Sima AA (2007) Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data CNS. Drugs 21(Suppl 1):13–23, discussion 45–16Google Scholar
  93. 93.
    Sima AA, Calvani M, Mehra M, Amato A (2005) Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 28:89–94PubMedCrossRefGoogle Scholar
  94. 94.
    Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633PubMedCrossRefGoogle Scholar
  95. 95.
    Abuaisha BB, Costanzi JB, Boulton AJ (1998) Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 39:115–121PubMedCrossRefGoogle Scholar
  96. 96.
    Jiang H, Shi K, Li X, Zhou W, Cao Y (2006) Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Tradit Chin Med 26:8–12PubMedGoogle Scholar
  97. 97.
    Tong Y, Guo H, Han B (2010) Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Acupunct Meridian Stud 3:95–103PubMedCrossRefGoogle Scholar
  98. 98.
    Wong R, Sagar S (2006) Acupuncture treatment for chemotherapy-induced peripheral neuropathy–a case series. Acupunct Med 24:87–91PubMedCrossRefGoogle Scholar
  99. 99.
    Donald GK, Tobin I, Stringer J (2011) Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupunct Med 29:230–233PubMedCrossRefGoogle Scholar
  100. 100.
    Schroeder S, Meyer-Hamme G, Epplee S (2012) Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med 30:4–7PubMedCrossRefGoogle Scholar
  101. 101.
    Xu WR, Hua BJ, Hou W, Bao YJ (2010) Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu 30:457–460PubMedGoogle Scholar
  102. 102.
    Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manage 43:87–95PubMedCrossRefGoogle Scholar
  103. 103.
    Campbell (2013) A randomized, double-blind study of “Scrambler” therapy versus sham for painful chemotherapy-induced peripheral neuropathy (CIPN). J Clin Oncol 31: suppl; abstr 9635Google Scholar
  104. 104.
    Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ (2013) A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. J Pain Palliat Care Pharmacother 27:359–364PubMedCrossRefGoogle Scholar
  105. 105.
    Marineo G (2003) Untreatable pain resulting from abdominal cancer: new hope from biophysics? Jop 4:1–10PubMedGoogle Scholar
  106. 106.
    Ricci M, Pirotti S, Scarpi E, Burgio M, Maltoni M, Sansoni E, Amadori D (2012) Managing chronic pain: results from an open-label study using MC5-A Calmare(R) device. Support Care Cancer 20:405–412PubMedCrossRefGoogle Scholar
  107. 107.
    Sabato AF, Marineo G, Gatti A (2005) Scrambler therapy. Minerva Anestesiol 71:479–482PubMedGoogle Scholar
  108. 108.
    Smith TJ, Coyne PJ, Parker GL, Dodson P, Ramakrishnan V (2010) Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare(R)) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 40:883–891PubMedCrossRefGoogle Scholar
  109. 109.
    Jin DM, Xu Y, Geng DF, Yan TB (2010) Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 89:10–15PubMedCrossRefGoogle Scholar
  110. 110.
    Pieber K, Herceg M, Paternostro-Sluga T (2010) Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med 42:289–295PubMedCrossRefGoogle Scholar
  111. 111.
    White CM, Pritchard J, Turner-Stokes L (2004) Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev CD003904Google Scholar
  112. 112.
    Dixit S, Maiya A, Shastry B (2013) Effect of aerobic exercise on quality of life in population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, randomized controlled trial. Qual Life ResGoogle Scholar
  113. 113.
    Kruse RL, Lemaster JW, Madsen RW (2010) Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy: “feet first” randomized controlled trial. Phys Ther 90:1568–1579PubMedCrossRefGoogle Scholar
  114. 114.
    Henke CC, Cabri J, Fricke L, Pankow W, Kandilakis G, Feyer PC, de Wit M (2014) Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV. Support Care Cancer 22:95–101PubMedCrossRefGoogle Scholar
  115. 115.
    Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Deirdre R. Pachman
    • 1
    Email author
  • James C. Watson
    • 2
  • Maryam B. Lustberg
    • 3
  • Nina D. Wagner-Johnston
    • 4
  • Alexandre Chan
    • 5
  • Larry Broadfield
    • 6
  • Yin Ting Cheung
    • 5
  • Christopher Steer
    • 7
  • Dawn J. Storey
    • 8
  • Kavita D. Chandwani
    • 9
  • Judith Paice
    • 10
  • Pascal Jean-Pierre
    • 11
  • Jeong Oh
    • 12
  • Jayesh Kamath
    • 13
  • Marie Fallon
    • 14
  • Herwig Strik
    • 15
  • Susanne Koeppen
    • 16
  • Charles L. Loprinzi
    • 1
  1. 1.Division of Medical OncologyMayo ClinicRochesterUSA
  2. 2.Department of NeurologyMayo ClinicRochesterUSA
  3. 3.Division of Medical Oncology, Stephanie Spielman Comprehensive Breast CenterThe Arthur G. James Cancer Hospital at the Ohio State UniversityColumbusUSA
  4. 4.Division of Medical Oncology, Internal MedicineWashington University School of MedicineSt. LouisUSA
  5. 5.Department of PharmacyNational University of SingaporeSingaporeSingapore
  6. 6.Department of PharmacyCancer Care Nova ScotiaHalifaxCanada
  7. 7.Border Medical OncologyWodongaAustralia
  8. 8.Edinburgh Cancer Research UK CentreUniversity of EdinburghEdinburghUK
  9. 9.Department of Radiation Oncology, James P.Wilmot Cancer Center, School of Medicine and DentistryUniversity of Rochester Medical CenterRochesterUSA
  10. 10.Cancer Pain Program, Division of Hematology-Oncology, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  11. 11.Department of Psychology, Neurocognitive Translational Research Lab, Biobehavioral Oncology Research ProgramUniversity of Notre DameNotre DameUSA
  12. 12.Center for Lasting Effects of Cancer Treatment, Department of General Internal MedicineMD Anderson Cancer CenterHoustonUSA
  13. 13.Department of PsychiatryUniversity of Connecticut Health CenterFarmingtonUSA
  14. 14.University of EdinburghEdinburghUK
  15. 15.Department of NeurologyUniversity of MarburgMarburgGermany
  16. 16.Department of NeurologyUniversity of Duisburg-EssenEssenGermany

Personalised recommendations